Key takeaway
What This Development Means
Recent GB CLP Agency Opinions show that HSE can reach different scientific classification outcomes from ECHA RAC on issues such as reproductive toxicity, STOT RE and aquatic hazards. For companies supplying both GB and EU markets, that creates a need for substance-by-substance checks of labels, SDSs and hazard communication assumptions.
What are GB CLP Agency Opinions?
GB CLP Agency Opinions are scientific assessments produced by HSE to support mandatory classification and labelling decisions in Great Britain. They evaluate hazard data for substances and can lead to legally binding classifications that determine how chemicals are labelled, packaged and communicated across the supply chain.
Why do HSE and ECHA RAC sometimes reach different conclusions?
HSE and RAC may interpret the same dataset differently, particularly where evidence is limited or uncertain. Differences can arise in how studies are weighted or how precaution is applied, leading to variations in hazard classification, such as reproductive toxicity categories or environmental M-factors.
Source basis: HSE GB mandatory classification and labelling publication table (XLSX), last modified 30 March 2026
GB CLP Agency Opinions indicate that the UK Health and Safety Executive has diverged from European Chemicals Agency Risk Assessment Committee positions in several recent classification decisions. The differences, identified in Agency Opinions covering substances such as 3,5-dimethylpyrazole, flazasulfuron, fosthiazate and penconazole, are relevant for professionals managing classification, labelling and regulatory compliance across Great Britain.
Examples Of Divergence In GB CLP Agency Opinions
A review of selected GB CLP Agency Opinions shows that HSE has taken a different view from ECHA RAC where it considers the underlying evidence to support an alternative hazard interpretation. For 3,5-dimethylpyrazole (CAS 67-51-6), the HSE Agency Opinion indicates the use of H360Fd for reproductive toxicity, rather than the H360FD wording adopted by RAC. This distinction reflects a difference in the strength of evidence for developmental toxicity. For flazasulfuron, HSE disagreed with RAC on the inclusion of muscle toxicity within specific target organ toxicity following repeated exposure (STOT RE), concluding that the available data did not support that element of the classification.Reproductive Toxicity And Environmental Classification Differences
In the case of fosthiazate (CAS 98886-44-3), HSE classified the substance as Repr. 2 (H361fd) rather than Repr. 1B, citing uncertainties in developmental toxicity data. This represents a lower level of concern compared with the RAC position. For penconazole (CAS 66246-88-6), HSE assigned a chronic aquatic M-factor of 1, in contrast to RAC’s M=10, indicating a different interpretation of long-term environmental hazard.Implications For Compliance And Regulatory Strategy
These GB CLP Agency Opinions suggest that classification outcomes may not always align between Great Britain and the EU. For companies operating across both jurisdictions, this could require substance-level reviews to confirm whether classifications, labels and safety data sheets remain appropriate for each market. Differences in hazard statements or M-factors may influence how risks are communicated and assessed within supply chains. Regulatory teams may therefore need to monitor HSE Agency Opinions alongside EU developments and evaluate whether updates to documentation or internal hazard assessments are warranted. A practical step is to track the HSE GB mandatory classification and labelling publication table and compare Agency Opinions with corresponding EU harmonised classifications.Related Articles
CLP Annex VI Update: EU Proposes Major Transfer Of SVHC And Hazardous Substances
The proposed CLP Annex VI update introduces harmonised classifications for over 100 hazardous substances, including SVHCs, PFAS and endocrine disruptors. The changes will impact labelling, safety data and product formulation across multiple sectors, requiring early compliance planning and supply chain engagement.
Austria Signals Endocrine Disruptor Proposal For Potassium Chlorate Under EU CLP
ECHA’s CLH intentions registry shows Austria plans a dossier for potassium chlorate, including proposed endocrine disruptor hazard classes for human health and the environment.
EU Court Rules Against Evonik In Silanamine Classification Dispute
EU Court upholds silanamine's hazardous classification, rejecting Evonik’s legal challenge.
